Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Spencer AJ. et al, (2021), Nature Communications, 12

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies

Spencer AJ. et al, (2021)

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

COVID-19 convalescent plasma: Interim recommendations from the AABB.

Cohn CS. et al, (2021), Transfusion, 61, 1313 - 1323

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2021), Nature, 590, E24 - E24

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in mice

Spencer AJ. et al, (2021)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.

Watanabe Y. et al, (2021), bioRxiv

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham SP. et al, (2020), npj Vaccines, 5

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein.

Wright D. et al, (2020), iScience, 23

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen N. et al, (2020), Nature, 586, 578 - 582

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.

Graham SP. et al, (2020), NPJ vaccines, 5

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world

Sharpe HR. et al, (2020), Immunology, 160, 223 - 232

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2020), bioRxiv : the preprint server for biology

Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination

Flaxman A. et al, (2019), Vaccine, 37, 494 - 501

Vaccination with the Staphylococcus aureus secreted proteins EapH1 and EapH2 impacts both S. aureus carriage and invasive disease

Elshina E. et al, (2019), Vaccine, 37, 502 - 509

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Allen ER. et al, (2018), Cell Reports, 25, 3750 - 3758.e4

Load More

Include forthcoming?